New drug cocktail targets tough stomach cancer in Last-Resort patients

NCT ID NCT05905887

Recruiting now Disease control Sponsor: Asan Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a combination of two drugs—rivoceranib and paclitaxel—in 48 adults with advanced gastrointestinal stromal tumors (GIST) that have a specific protein marker (high P-glycoprotein) and have stopped responding to three standard treatments. The goal is to see if the combo can control the disease. Participants take both drugs daily or weekly in 28-day cycles.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: rivoceranib and paclitaxel
What this could lead to: If successful, this combination could offer a new treatment option for people with a hard-to-treat form of GIST that has stopped responding to standard therapies.
What could go wrong: This is a small, early-phase trial (48 people) with no control group, so results may not apply broadly. The drugs can cause side effects like nerve damage, low blood counts, and high blood pressure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastrointestinal stromal tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTROINTESTINAL STROMAL TUMORS

Contacts and locations

Locations

Asan Medical Center, University of Ulsan College of Medicine
RECRUITING

Seoul, Seoul, 138-736, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.